Skip to main content

Advertisement

SpringerLink
Log in

Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil

  • Case Report
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  1. Colorectal Cancer Screening and Surveillance—American Family Physician. Accessed March 11, 2015. http://www.aafp.org/afp/2015/0115/p93.html.

  2. Van Kuilenburg ABP. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer. 2004;40(7):939–50. doi:10.1016/j.ejca.2003.12.004.

    Article  PubMed  Google Scholar 

  3. Van Kuilenburg ABP, Maring JG, Schalhorn A, Terborg C, Schmalenberg H, Behnke D, et al. Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14 + 1G> a mutation in the dihydropyrimidine dehydrogenase gene. Nucleosides Nucleotides Nucleic Acids. 2008;27(6–7):692–8. doi:10.1080/15257770802145009.

    Article  PubMed  Google Scholar 

  4. Ezzeldin H, Diasio R. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer. 2004;4(3):181–9. doi:10.3816/CCC.2004.n.018.

    Article  CAS  PubMed  Google Scholar 

  5. Blasco H, Boisdron-Celle M, Bougnoux P, Gilles C, Tournamille J-F, Ciccolini J, et al. A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient. Br J Clin Pharmacol. 2008;65(6):966–70. doi:10.1111/j.1365-2125.2008.03106.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Ciccolini J, Mercier C, Dahan L, Evrard A, Boyer J-C, Richard K, et al. Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency. Cancer Chemother Pharmacol. 2006;58(2):272–5. doi:10.1007/s00280-005-0139-8.

    Article  CAS  PubMed  Google Scholar 

  7. Van Kuilenburg ABP, Vreken P, Abeling NGGM, Bakker HD, Meinsma R, Van Lenthe H, et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet. 1999;104(1):1–9. doi:10.1007/PL00008711.

    Article  PubMed  Google Scholar 

  8. Mercier C, Ciccolini J. Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy. Clin Colorectal Cancer. 2006;6(4):288–96. doi:10.3816/CCC.2006.n.047.

    Article  CAS  PubMed  Google Scholar 

  9. van Kuilenburg ABP, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, De Abreu RA, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res. 2000;6(12):4705–12.

    PubMed  Google Scholar 

  10. Boisdron-Celle M, Remaud G, Traore S, Poirier AL, Gamelin L, Morel A, et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett. 2007;249(2):271–82. doi:10.1016/j.canlet.2006.09.006.

    Article  CAS  PubMed  Google Scholar 

  11. Giorgio E, Caroti C, Mattioli F, Uliana V, Parodi MI, D’Amico M, et al. Severe fluoropyrimidine-related toxicity: clinical implications of DPYD analysis and UH2/U ratio evaluation. Cancer Chemother Pharmacol. 2011;68(5):1355–61. doi:10.1007/s00280-011-1709-6.

    Article  CAS  PubMed  Google Scholar 

  12. Ciccolini J, Mercier C, Evrard A, Dahan L, Boyer J-C, Duffaud F, et al. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther Drug Monit. 2006;28(5):678–85. doi:10.1097/01.ftd.0000245771.82720.c7.

    Article  CAS  PubMed  Google Scholar 

  13. National Guideline Clearinghouse/Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Accessed March 11, 2015. http://www.guideline.gov/content.aspx?id=47994.

  14. Magnani E, Farnetti E, Davide N, Casali B, Savoldi L, Focaccetti C, et al. Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule. Intern Emerg Med. 2013;8(5):417–23. doi:10.1007/s11739-013-0936-8.

    Article  PubMed  Google Scholar 

  15. Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, et al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol. 2015. doi:10.1200/JCO.2015.63.1325.

  16. Barni S, Ghidini A, Coinu A, Borgonovo K, Petrelli F. A systematic review of raltitrexed-based first-line chemotherapy in advanced colorectal cancer. Anticancer Drugs. 2014;25(10):1122–8. doi:10.1097/CAD.0000000000000133. Review.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Massachusetts Medical School, Worcester, MA, USA

    Saranya Kodali

  2. Department of Medicine, Division of Hematology and Oncology, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA, 01655, USA

    Venu Bathini & Eswar Tipirneni

  3. Department of Radiation Oncology, University of Massachusetts Medical School, Worcester, MA, USA

    Paul Rava

Authors
  1. Saranya Kodali
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Venu Bathini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul Rava
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eswar Tipirneni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eswar Tipirneni.

Ethics declarations

Conflict of Interest

The authors declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kodali, S., Bathini, V., Rava, P. et al. Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil. J Gastrointest Canc 48, 66–69 (2017). https://doi.org/10.1007/s12029-015-9797-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-015-9797-x

Keywords

Search

Navigation